Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European ...

Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the ...

PARIS--(BUSINESS WIRE)--Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA™ technology to accelerate the Japanese healthcare leader’s RNA-targeted ...

AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast ...

Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for the supplemental biologics licence application (sBLA) of Enhertu (fam-trastuzumab ...

Merck will pay Daiichi Sankyo $5.5 billion in the agreement, which has a total potential consideration of up to $22 billion. Daiichi Sankyo aims for at least $6 billion of revenue from its oncology ...

TOKYO, May 28 (Reuters) - Japan's No.3 drugmaker Daiichi Sankyo <4568.T> intends to keep its Indian subsidiary Ranbaxy Laboratories listed, Daiichi's incoming president said on Friday, denying ...

TOKYO, Jan 5 (Reuters) - Japan's third-largest drugmaker, Daiichi Sankyo Co <4568.T>, said on Monday it would book an appraisal loss of 359.5 billion yen ($3.9 billion) on a parent-company basis on ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from April ...

ABU DHABI, 14th August, 2025 (WAM) – Emirates Global Aluminium, the largest industrial company in the United Arab Emirates and the world’s biggest ‘premium aluminium’ producer, today announced an ...